%0 Journal Article
%T EGFR变构抑制剂在小细胞肺癌治疗中的作用和未来发展<br>The Role and Future Development of EGFR Allosteric Inhibitors in the Treatment of Small Cell Lung Cancer
%A 贾硕磊
%A 周庆发
%J Hans Journal of Medicinal Chemistry
%P 185-195
%@ 2331-8295
%D 2024
%I Hans Publishing
%R 10.12677/hjmce.2024.123021
%X 表皮生长因子受体(EGFR)过表达和突变与非小细胞肺癌的发生密切相关。EGFR激活突变作为非小细胞肺癌的致癌因素，EGFR小分子抑制剂的开发也不断在进行。然而从2016年首次报道EGFR<sup>C797S</sup>突变成为第三代不可逆抑制剂的主要耐药机制以来，至今仍未有对抗EGFR<sup>C797S</sup>三级突变特效药获得审批。因此，开发第四代EGFR抑制剂具有重要意义。本文综述了EGFR继发性突变的过程以及EGFR变构抑制剂的最新药物化学进展。我们希望这些数据能启发读者新的想法，开发出对EGFR<sup>C797S</sup>突变有效的新型第四代EGFR变构抑制剂。<br />
Epidermal growth factor receptor (EGFR) overexpression and mutations are closely associated with the development of non-small cell lung cancer. EGFR-activating mutations function as oncogenic drivers in non-small cell lung cancer, driving ongoing efforts in the development of small-molecule inhibitors targeting EGFR. However, since the identification of the EGFR<sup>C797S</sup> mutation in 2016 as the primary resistance mechanism for third-generation irreversible inhibitors, no potent drug targeting the EGFR<sup>C797S</sup> tertiary mutation has been approved. Consequently, the development of fourth-generation EGFR inhibitors is of paramount importance. In this article, we provide a comprehensive overview of the process of acquired EGFR mutations and recent advancements in medicinal chemistry related to acquired-resistant fourth-generation EGFR small-molecule inhibitors, with a particular focus on allosteric and reversible inhibitors designed to counteract the EGFR<sup>C797S</sup> mutation. We aim for these insights to inspire readers with innovative approaches in developing novel fourth-generation EGFR small-molecule inhibitors that effectively combat the EGFR<sup>C797S</sup> mutation.
%K EGFR抑制剂，变构抑制剂，非小细胞肺癌<br>EGFR Inhibitors
%K Allosteric Inhibitors
%K Non-Small Cell Lung Cancer
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=92763